Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Leukemia. 2015 Apr 17;29(8):1702–1712. doi: 10.1038/leu.2015.99

Figure 2. Increased BCL2 eliminates dinaciclib's anti-DLBCL activity.

Figure 2

(a) Riva and U2932 cells were exposed to 1:1000 DMSO or dinaciclib at the indicated times and concentrations and blotted as indicated. (b) Expression of BCL2 and MCL1 in 23 DLBCL cell lines, normalized to GAPDH, and compared to IC50 (Log10) of dinaciclib using linear regression analysis. (c) Fold change GFP+ cells in lines infected with BCL2 or vector after recovery from 1:1000 DMSO (0) or dinaciclib at the indicated concentrations for 24 hours. (d) Comparison of cell viability after 24 hours dinaciclib exposure between parental and BCL2-over-expressing SU-DHL-4 and TMD8 cells. Mean of quadruplicates ± SEM. (e) BCL2-over-expressing SU-DHL-4 and TMD8 cells were exposed to 1:1000 DMSO or dinaciclib at the indicated times and concentrations and blotted as indicated. (b and c) Mean ± SEM of triplicates.